TOKYO, Feb 16, 2024 - (JCN Newswire) - - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained ...

TOKYO, Sept 26, 2022 - (JCN Newswire) - - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced today that they have obtained ...

Methotrexate The effectiveness of oral vs subcutaneous methotrexate for the treatment of psoriasis in a registry is reported. More patients with psoriasis who were treated with subcutaneous ...

Please provide your email address to receive an email when new articles are posted on . Subcutaneous methotrexate is safe in clinical practice, and is continued longer and better tolerated than other ...

Subcutaneous tocilizumab, either as monotherapy or in combination with methotrexate, demonstrated greater efficacy than methotrexate alone and was well tolerated in patients with active rheumatoid ...

Subcutaneous tocilizumab, alone or with methotrexate, showed superior efficacy over methotrexate monotherapy in treating rheumatoid arthritis in Chinese patients. The trial demonstrated higher ACR20 ...

Please provide your email address to receive an email when new articles are posted on . Olokizumab demonstrated superiority compared with placebo and non-inferiority compared with adalimumab in ...

Subcutaneous (subQ or SQ) injections are shots given in the fatty tissue layer (subcutaneous fat) under your skin. Your skin has many layers, and the subcutaneous layer is beneath the epidermis and ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. WARNING: Important safety information is provided in a boxed warning ...

Oral, rather than subcutaneous, methotrexate avoids weekly injections, reduces costs and might improve quality of life in children with Crohn's disease. 226 children with Crohn's disease were included ...

LONG BEACH, Calif. -- Methotrexate, during and after surgery for primary retinal detachment, has produced "amazing" early results in preventing proliferative vitreoretinopathy (PVR), according to ...

Methotrexate is an immunosuppressive agent which blocks DNA synthesis by inhibiting dihydrofolate reductase. It is typically given either as a single weekly dose of 7.5 to 25 mg per week or divided ...